Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 38.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 539,405 shares of the company's stock after selling 340,000 shares during the period. Vaxcyte makes up about 1.8% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 13th biggest holding. Frazier Life Sciences Management L.P. owned approximately 0.43% of Vaxcyte worth $44,156,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in PCVX. Nisa Investment Advisors LLC increased its holdings in Vaxcyte by 21.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company's stock valued at $220,000 after purchasing an additional 475 shares in the last quarter. Avior Wealth Management LLC increased its holdings in Vaxcyte by 21.1% in the 4th quarter. Avior Wealth Management LLC now owns 6,456 shares of the company's stock valued at $528,000 after purchasing an additional 1,124 shares in the last quarter. Blue Trust Inc. increased its holdings in Vaxcyte by 125.1% in the 4th quarter. Blue Trust Inc. now owns 835 shares of the company's stock valued at $68,000 after purchasing an additional 464 shares in the last quarter. KBC Group NV increased its holdings in Vaxcyte by 78.0% in the 4th quarter. KBC Group NV now owns 4,775 shares of the company's stock valued at $391,000 after purchasing an additional 2,092 shares in the last quarter. Finally, Chicago Partners Investment Group LLC increased its holdings in Vaxcyte by 9.2% in the 4th quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company's stock valued at $440,000 after purchasing an additional 458 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

Shares of PCVX stock traded down $1.41 during trading hours on Friday, hitting $32.54. 1,763,863 shares of the company were exchanged, compared to its average volume of 1,367,883. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The business's 50-day simple moving average is $38.53 and its two-hundred day simple moving average is $69.43. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of -7.07 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period last year, the company earned ($0.85) EPS. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at $11,351,794.37. This trade represents a 4.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 3.10% of the company's stock.

Analyst Upgrades and Downgrades

PCVX has been the subject of several recent research reports. Cantor Fitzgerald initiated coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Bank of America lowered their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Finally, Guggenheim restated a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Vaxcyte has a consensus rating of "Buy" and an average price target of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.